IPP Bureau
Orchid Pharma receives DCGI approval for combination of Cefepime and Enmetazobactam
By IPP Bureau - June 07, 2024
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Torrent inks licensing agreement with Takeda to commercialize its novel gastrointestinal drug in India
By IPP Bureau - June 07, 2024
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Merck completes € 180 million investment to expand Schnelldorf Distribution Center
By IPP Bureau - June 07, 2024
Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany
AbbVie announces positive results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine for high FR? expressing platinum-sensitive ovarian cancer
By IPP Bureau - June 07, 2024
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Health Ministry and Defence Ministry ink MoU to set up dedicated Tele MANAS cell for armed forces
By IPP Bureau - June 06, 2024
The special Tele MANAS cell to serve as a dedicated mental health assistance helpline for all Armed Forces beneficiaries across country
Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer
By IPP Bureau - June 06, 2024
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Shilpa Biologicals files Type IV DMF of recombinant Human Albumin 20% with USFDA
By IPP Bureau - June 06, 2024
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
GSK disagrees with ruling by the Delaware State Court on Zantac (ranitidine) litigation
By IPP Bureau - June 06, 2024
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Bayer and Samsung take action against sleep disturbances associated with menopause
By IPP Bureau - June 06, 2024
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Melissa Seymour to join Lilly as executive vice president of Global Quality
By IPP Bureau - June 06, 2024
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Melissa Seymour to join Lilly as executive vice president of Global Quality
By IPP Bureau - June 06, 2024
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
AstraZeneca completes acquisition of Fusion Pharmaceuticals
By IPP Bureau - June 05, 2024
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma
By IPP Bureau - June 05, 2024
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
AstraZeneca’s Tagrisso plus chemo recommended for approval in EU
By IPP Bureau - June 05, 2024
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda
By IPP Bureau - June 05, 2024
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
